← Back to Search

Monoclonal Antibodies

Bimekizumab for Ankylosing Spondylitis (BE MOBILE 2 Trial)

Phase 3
Waitlist Available
Research Sponsored by UCB Biopharma SRL
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (day 1) until safety-follow-up (up to week 72)
Awards & highlights

BE MOBILE 2 Trial Summary

This study is evaluating whether a drug called bimekizumab can help treat people with ankylosing spondylitis.

Eligible Conditions
  • Ankylosing Spondylitis

BE MOBILE 2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (day 1) until safety-follow-up (up to week 72)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (day 1) until safety-follow-up (up to week 72) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Spondylarthritis
Secondary outcome measures
Ankylosing Spondylitis Disease Activity Score major improvement (ASDAS-MI) at Week 16
Assessment of SpondyloArthritis International Society (ASAS) 5/6 response at Week 16
Assessment of SpondyloArthritis International Society (ASAS) partial remission (PR) at Week 16
+13 more

BE MOBILE 2 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BimekizumabExperimental Treatment1 Intervention
Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
Group II: PlaceboPlacebo Group2 Interventions
Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bimekizumab
2018
Completed Phase 3
~6510

Find a Location

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor
101 Previous Clinical Trials
21,091 Total Patients Enrolled
UCB CaresStudy Director001 844 599 2273 (UCB)
205 Previous Clinical Trials
44,618 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
2019. "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03928743.
~56 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top